ABIONYX Pharma: €3.5 Million in Cash Reserves and a Major Bet Against Sepsis
ABIONYX Pharma announces its annual results for 2025 and outlines its strategic directions focused on actively preparing for the next clinical phase in sepsis, as well as continuing industrial bioproduction activities. The company benefits from extended financial visibility until the end of June 2027 thanks to funding received under the France 2030 initiative.
Strategic Deployment of Bioproduct through Compassionate Access Authorizations
ABIONYX Pharma has strategically chosen to provide its bioproduct free of charge under Compassionate Access Authorizations (CAA). This approach aims to broaden patient access to innovative treatments while enhancing the clinical experience and medical validation of the product under real-world usage conditions. The group is actively pursuing the optimization of industrial bioproduction since being named a winner of the i-Demo tender under the France 2030 plan. The clinical value of the bioproduct has been strengthened through a partnership with the IHU Sepsis.
Financial Overview and Government Support
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
ABIONYX Pharma has a cash reserve of €3.5 million as of December 31, 2025. The company was a recipient of the 'i-Demo' project call under the France 2030 plan and received €8.7 million in state support to fight sepsis, with €6.5 million still to be received. Based on its current cash reserves, independent of this funding, the company maintains extended financial visibility until the end of 2026, which will extend to the end of June 2027 upon receipt of the remaining France 2030 funds.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T1 2026
Key reported figures
Revenue: 0,8 millions d'euros
Quarterly revenue: 0,8 millions d'euros
Revenue growth: -16,2 %
Guidance from the release
€2.6 million in business already secured (non-biotech IRIS Pharma revenue only; core strategic biotech business generated zero revenue in Q1)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
